Enterprise Value
222.1M
Cash
310.5M
Avg Qtr Burn
-29.42M
Short % of Float
13.74%
Insider Ownership
32.60%
Institutional Own.
64.31%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Follicular lymphoma, Mantle cell lymphoma, Diffuse large B cell lymphoma | Approved Update | |
Camidanlumab Tesirine (CD25) Details Solid tumor/s, Hodgkin Lymphoma, Cancer | BLA Submission | |
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Blood cancer, Cancer, Diffuse large B cell lymphoma | Phase 2 Data readout | |
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Non-Hodgkin lymphoma, Blood cancer, Cancer | Phase 1b Interim update | |
ADCT-601 (AXL) Details Solid tumor/s, Cancer | Phase 1b Interim update | |
ADCT-602 (CD22) Details Acute lymphoblastic leukemia | Phase 1a Data readout |